Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2016-10-18 Regulatory Filings
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-10-18 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) related to a sales agreement for common stock offering. It details the terms of the offering, company overview, risk factors, and other information typical of a securities offering prospectus. It is not a financial report, earnings release, or management discussion. It is a capital raising document describing the offering of shares and related terms. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, confirming it is not a brief announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2016-10-17 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a formal communication related to a securities registration process, specifically requesting the SEC to make the registration effective earlier than usual. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to capital markets activity but is not itself a financial report or earnings release. Given the nature of the document as a formal regulatory request and communication, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2016-10-13 English
Regulatory Filings 2016
Regulatory Filings
2016-10-13 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering. It includes a base prospectus for offering common stock, preferred stock, debt securities, and warrants up to $150 million. The document is a detailed registration statement and prospectus, not a financial report, earnings release, or management discussion. It is related to capital raising activities and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice.
2016-10-03 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 3, 2016, reporting the entry into a material definitive agreement related to an at-the-market issuance Common Stock Sales Agreement and an amendment to a Senior Secured Convertible Note and Warrant. The content focuses on financing activities, specifically the company's ability to sell common stock up to $50 million through a sales agent and amendments related to convertible notes. There are no financial statements or quarterly/yearly financial results presented, nor is this a report of voting results, management changes, or legal proceedings. The primary subject is an update on capital raising and financing arrangements. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (6666 characters) and detailed description of the financing agreement support this classification with high confidence.
2016-10-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.